Epithelial downgrowth following clear corneal phacoemulsification in a buphthalmic eye

Epithelial downgrowth is a rare complication which can occur following anterior segment surgery and penetrating ocular injury. A prevalence as high as 16–29% among eyes enucleated after cataract surgery has been reported in the older literature, but advancements in the microsurgical techniques have decreased that rate to less than 0.2%. To our knowledge only two cases of epithelial downgrowth following clear corneal phacoemulsification have been reported. We present the clinical and histopathological features, and the successful surgical management, of a patient with extensive intraocular involvement of epithelial downgrowth with following clear corneal phacoemulsification.

Case report
A 26 year old man was followed up for bilateral congenital glaucoma. He had undergone several bilateral trabeculectomies in the past. Preoperatively his intraocular pressures (IOP) were well controlled with no medication. He underwent phacoemulsification with implantation of a poly(methylmethacrylate) (PMMA) lens through a 5 mm superior clear corneal wound in the right eye. The corneal wound was closed with Nylon sutures, as the eye wall was thin secondary to buphthalmos and the temporal end of the wound was irregular extending to the limbus. At the end of the surgery the wound appeared secured with a deep anterior chamber. Two weeks postoperatively he presented with wound leak from the corneal section. A conjunctival hood was fashioned over the corneal wound in an attempt to prevent wound leak. Four weeks later he developed an epithelial downgrowth in the form of a retrocorneal membrane with involvement of the iris from the 7 o’clock to 2 o’clock position (fig 1, top). He underwent a corneosclero-iridocyclectomy with removal of the IOL and posterior capsule combined with anterior vitrectomy. No adjuvant cryotherapy was used. A horseshoe-shaped corneoscleral graft was sutured in place. Histopathological examination confirmed extensive downgrowth of non-keratinised stratified squamous epithelium involving the cornea, the angle, anterior and posterior surface of the iris, the ciliary body, and extending on to the posterior capsule (fig 1, bottom and fig 2, top). At 17 months follow up he had a vision of 6/12 with aphakic correction and there was no evidence of recurrence of the downgrowth (fig 2, bottom).

Comment
Epithelial downgrowth is characterised by progressive advancement of an epithelial membrane onto the intraocular surfaces and it can lead to intractable and painful glaucoma. It can occur in three forms: (1) “pearl tumours” of the iris, (2) epithelial cyst, (3) growth of epithelium as a sheet on to the anterior chamber structures. This last form has been shown to have the worst prognosis.

Although there is no single predisposing factor, wound fistula, damage to the corneal endothelium, and corneal stromal vascularisation can have a role in the pathogenesis of the epithelial invasion. Various methods have been tried in the treatment of epithelial downgrowth. It has been shown that patients treated surgically underwent fewer recurrences than patients managed conservatively. However, surgical management of epithelial downgrowth is difficult, particularly when the anterior chamber contains sheets of epithelium. Knauf et al reported surgical success following surgical excision of a localised cystic downgrowth. Extensive disease involvement is associated with a poor outcome. We feel that early detection and surgical intervention can result in improved outcome even in cases where the downgrowth has extensive intraocular involvement as demonstrated in this case. Experimental evidence suggests that the presence of endothelium inhibits epithelial downgrowth through direct intercellular interactions. There are previous reports documenting decreased endothelial cell density in eyes with congenital glaucoma. It is possible that the decreased endothelial cell count combined with persistent wound leak would have contributed to the extensive downgrowth of the epithelium in our patient. We hope this case report highlights this rare complication of small incision cataract surgery.

S Srinivasan, D H Jones, J L Jay
Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, UK
F Roberts
Department of Pathology, Western Infirmary, Glasgow, UK
Correspondence to: Sathish Srinivasan, St Paul’s Eye Unit, Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK; sathish@tiscali.co.uk
Accepted for publication 2 December 2002

References
Postscript


Posterior uveal effusion syndrome after trabeculectomy in an eye with ocular venous congestion

Schepps and Brockhurst, in 1963, used the term uveal effusion syndrome to describe spontaneous bilateral serous detachments of the choroid and ciliary body with exudative retinal detachment, primarily occurring in middle-aged healthy males. Many cases have been reported since them, especially in nanophthalmic eyes. We report an interesting case of a young, healthy female patient with mild ocular venous congestion who developed posterior serous retinal detachment and uveal effusions after trabeculectomy for open angle glaucoma.

Case report

A 32 year old white female was referred to the glaucoma service at Doheny Eye Institute for high intraocular pressure in the left eye. Visual acuity was 20/20 right eye and 20/25 left eye. Manifest refraction was -2.75+1.50 ×13 right eye and +0.50+2.00×160 left. An afferent pupillary defect was noted in the left eye. Application intraocular pressures were 17 mm Hg right eye and 36 mm Hg left.

Slit lamp examination of both eyes revealed dilated and tortuous conjunctival and episcleral vessels, although more obvious in the left eye than the right eye. The anterior chambers were deep and quiet. The cornea and episcleral vessels, although more obvious in the left eye than the right eye, were noted in Schlemm’s canal of both eyes. Cup showed open, grade IV Shafer angles with chambers were deep and quiet. The cornea was noted to be more pronounced in the left eye.
Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion

No proved treatment exists for ischaemic macular oedema associated with branch retinal vein occlusion (BRVO) despite the potential for significant visual loss in affected eyes.

We report a patient with an ischaemic BRVO with associated macular oedema treated with intravitreal triamcinolone acetonide.

Case report

A 38 year old man was referred to our department with a 6 week history of acute visual loss in his right eye (RE). On examination, visual acuity was 6/60 RE and 6/6 LE. A right relative afferent pupillary defect was present. Intraocular pressures were 9 and 10 mm Hg, respectively. Anterior segment examination showed no evidence of neovascularisation. There was no vitreous inflam-
mation. Dilated fundus examination revealed a right inferotemporal BRVO with macular oedema. Collateral disc vessels were present. Systemic and haematological examinations, including full blood count, erythrocyte sedimentation rate, C-reactive protein, clotting screen, serum angiotensin converting enzyme, serum cholesterol and triglycerides, clotting screen, chest x ray, and ECG, were negative for systemic vascular or vasculitic disease.

At review 4 months later, right visual acuity had reduced to counting fingers. Fluorescein angiography showed significant macular ischaemia and non-perfusion with a broken foveal capillary ring (fig 1A). There was diffuse leakage and additional masking of the left eye before first intravitreal injection of triamcinolone. Fluorescein angiography showed significant macular ischaemia and non-perfusion with a broken foveal capillary ring (fig 1A). There was diffuse leakage and additional masking of the left eye before first intravitreal injection of triamcinolone. Triamcinolone, 4 mg (0.1 ml), was injected through the inferior pars plana, 4 mm from the limbus.

Triamcinolone, 4 mg (0.1 ml), was injected through the inferior pars plana, 4 mm from the limbus.

Povidone-iodine 5% (Betadine) was used for anaesthesia. Povidone-iodine 5% (Betadine) was used for anaesthesia.

The patient was offered an intravitreal injection of triamcinolone acetonide (Kenalog, Bristol-Myers Squibb, UK). Topical 0.5% amethocaine was used for anaesthesia. Povidone-iodine 5% was then applied to the conjunctiva. Triamcinolone, 4 mg (0.1 ml), was injected through the inferior pars plana, 4 mm from the limbus.

Two weeks post-injection, visual acuity had improved to 6/36 in the right eye. On biomicroscopic examination the macula oedema had resolved fully. Central macular thickness measured 160 µm with a normal foveal contour (fig 2B).

Visual acuity at 3 months post-injection was 6/24 with no macular oedema detectable on biomicroscopic examination.

Comment

Macular oedema caused by BRVO carries a variable visual prognosis. After 3 years, 23% of untreated eyes will have visual acuity 20/200 or worse. Only 37% of eyes will gain two or more lines of visual acuity. The Branch Vein Occlusion Study group showed that argon laser grid photocoagulation can improve visual acuity in eyes with BRVO with macular oedema reducing vision to 20/40 or worse. However, laser treatment is inappropriate in eyes with foveal capillary non-perfusion. Eyes with BRVO and a broken foveal capillary ring have a poorer prognosis for visual acuity. Although one study reported a favourable visual outcome in 91% of eyes with BRVO and macular oedema associated with incomplete macular perfusion, the majority of cases with a good visual outcome were presented with visual acuities of 20/100 or better. Poor presenting visual acuity is corre-
lated to poor visual prognosis.

In this case, a patient with a chronic BRVO and ischaemic macular oedema had complete resolution of the macular oedema 2 weeks following intravitreal injection of triamcinolone. The resolution of macular oedema was associated with a significant improvement in visual acuity from counting fingers to 6/24. This final visual acuity was presumably limited because of residual ischaemic macular damage.

Although the mode of action by which triamcinolone induces resolution of macular oedema remains poorly understood, in vitro studies and clinical observations indicate that triamcinolone has the capacity to reduce the permeability of the outer blood-retinal bar-
rier.

Intravitreal triamcinolone has been shown to be safe and effective when used for the treatment of cystoid macular oedema caused by uveitis, diabetic maculopathy, central retinal vein occlusion, and post-cataract surgery. IOP elevation may occur in up to 50% of eyes after triamcinolone injection. Other potential risks include cataract development, retinal detachment, and endophthalmitis. Despite good initial anatomo-
cal and visual response to intravitreal triamcinolone when used in these conditions, macular oedema has been reported to recur following treatment, often necessitating repeated injections. Further follow up is required to determine if macular oedema recurs following treatment in branch retinal vein occlusions.

This case suggests that the use of intra-
vitreal triamcinolone acetonide for the treat-
ment of macular oedema due to BRVO warrants further study.

References

360 degree giant retinal tear as a result of presumed non-accidental injury

Giant retinal tears are defined as retinal tears extending 90 degrees or more around the eye. There was no previous medical history and the child was not on any weight. There was no previous medical history and the college recommendations detected no retinoschisis. Screening for retinopathy of prematurity extending 90 degrees or more around the eye was normal. An magnetic resonance image (MRI) revealed areas of cystic encephalomalacia associated with haemorrhagic elements and areas of cavitation parasagittally in the frontal and left parietal lobes consistent with periorbital oedema with subconjunctival haemorrhage. Other manifestations included a clotting screen which was entirely normal.

Case report

A 4 month old girl presented with iris heterochromia, bruising over the left eye, a right relative afferent pupillary defect, and a right vitreous haemorrhage. She was born at 28 weeks by normal vaginal delivery, screening for retinopathy of prematurity by the college recommendations detected no abnormality. She was bottle fed and gaining weight. There was no previous medical history and the child was not on any medication. The mother was an injecting drug user and the girl was on the child protection register, subject to an interim care order at the time of presentation.

A number of investigations were performed, including a clotting screen which was normal. An magnetic resonance image (MRI) revealed areas of cystic encephalomalacia associated with haemorrhagic elements and areas of cavitation parasagittally in the frontal and left parietal lobes consistent with multiple contusions.

On examination the child did not fix to light or a target with the right eye and there was no response to the optokinetic nystagmus drum. There was no red reflex visible in the right eye and a right exotropia was present. Cycloplegic refraction revealed a refractive error of −0.50/−2.00 × 30 in the left eye. B-scan revealed a mass of tissue centrally with a corrugated membranous configuration and high reflectivity. Electrophysiological findings were consistent with severe retinal dysfunction with a flat ERG on the right. There was also evidence of occipital asymmetry suggestive of left hemisphere dysfunction. Occipital flash VEPs to independent testing of each eye were detectable but were broadened and degraded. There was consistent conspicuous asymmetry in the occipital distribution of the responses that was present for the majority of pattern and flash VEP recordings.

Examination under anaesthesia revealed eyes of normal axial lengths. An anterior lens opacity was present in the right eye with a 360 degree giant retinal tear resulting in a total retinal detachment. There was no anterior funnel configuration, the mass of retina posteriorly confirmed the previous ultrasound findings. A vitreoretinal opinion was sought but the retina was fibrosed and thickened and not considered viable for surgical repair. Examination of the left eye was entirely normal.

Comment

Giant retinal tears are commonly idiopathic (70%) but are associated with trauma in about 20% of cases. Myopia is a common finding with 40% of eyes having more than 8 dioptres of myopia. Non-traumatic giant retinal tears occur more frequently in males and tears occur in the fellow eye in about 10% of cases. Kanski reviewed 100 eyes with giant retinal tears and found that 71% of eyes with non-traumatic giant retinal tears were myopic and severe retinal pathological findings were present in 57% of fellow eyes. Idiopathic giant tears have been found in identical twins raising the question of genetic influences in the pathogenesis of this condition.

Ocular injury is the presenting sign of physical abuse in 4–6% of cases although it may be evident in up to 40% of abused children. The commonest abnormality is retinal haemorrhage, which is the cardinal sign of shaken baby syndrome, occurring in some 80% of cases. The next most common finding is periorbital oedema with subconjunctival haemorrhage. Other manifestations reported include retinal detachment and retinoschisis.

The collection of signs seen in this case, including retinal detachment, anterior lens opacity, bruising of the contralateral eye, MRI and electrophysiological findings are highly suggestive of NAI. The electrophysiological findings were suggestive of multiple contusions to the head and it is our belief that the giant retinal tear and subsequent retinal detachment occurred as a result of a direct blow to the eye rather than violent shaking. This is, to our knowledge, the first reported case of a 360 degree retinal tear associated with NAI. Practitioners should be alert to the possibility of NAI when faced with a giant retinal tear in a young child.

C Lash, C P R Williams, A J Luff, P R Hodskins
Southampton Eye Unit, Southampton General Hospital, Tremaon Road, Southampton SO16 6YD, UK
Correspondence to: Mr Stephen C Lash, Southampton Eye Unit, Southampton General Hospital, Tremaon Road, Southampton SO16 6YD, UK; stevelash@doctors.org.uk
Accepted for publication 15 April 2003

References


CVN subtype in first eyes predicts severity of ARM in fellow eyes

I would like to congratulate Abugreen et al1 for publishing an interesting article on the relation between choroidal neovascularisation (CNV) in one eye and age related maculopathy (ARM) in the opposite eye. However, the required data to support some of the authors’ conclusions were not given in the paper.

The authors stated in the abstract that “the area occupied by the CNV in the first eye also influenced severity of ARM changes in the fellow eye.” In the results section it was stated that “age, sex, cardiovascular disorder, and smoking status were not significant predictors for ARM severity in the model.”

In the statistical analysis section of Methods, as well as in the footnotes to Table 5, it was mentioned that the “CVN subtype” was the dependent variable and not the “ARM severity in the fellow eye.” Therefore, the model was attempting to predict the ‘type of CNV in the same eye,’ and not the “ARM severity in the fellow eye” using the independent variables age, sex, cardiovascular disorder, etc. In addition, there appear to be typographical errors in the values in Table 5. 0.57 should read 0.057, 0.19 should read 0.019.

Also in Table 5, the odds ratio of stage 3 ARM (soft indistinct drusen or reticular drusen with pigmentary irregularities) being 9.48 times more than no ARM predicting an occult CNV over a classic CNV was also misleading. This is because the individual coefficients of the independent variables reflect the contribution of these factors (including area of the CNV lesion) to the variance of the dependent variable (the CNV subtype). In order to examine the effect of CNV subtype in one eye on the severity of ARM in the other eye, perhaps the authors should collapse the five possible values for the severity of ARM into two and designate this the dependent variable in the logistic regression model. Since the logistic regression model predicts the log odds that an observation will have an indicator equal to 1, to facilitate interpretation of odds ratios, it is crucial to specify which of the condition (“occult CNV” or “classic CNV”) is designated as 1 (the counterpart being 0). Alternatively, they could perform “multiple linear regression” and designate “severity of ARM” as the dependent variable with five possible values. In either of these two alternatives, area of lesion (in the eye with CNV), age, etc could be additional independent variables.

If the authors were to compare only “severity of ARM” with “CNV subtype” (four possible values), Kendall’s rank correlation is also a reasonable approach.

L Tong
Singapore National Eye Centre, 11, 3rd Hospital Avenue, Singapore 168751; Louistong@hotmail.com
Accepted for publication 11 May 2003

Reference

A new look at ophthalmodynamometry

It was with great interest that I read the article by Jonas. It is indeed noteworthy that efforts are being undertaken for revising ophthalmodynamometry. This is especially pertinent as this method is, despite the many modern techniques published within the past 20 years, the only way to gain insights regarding the pressure present at the eye’s central retinal vessels. A direct measuring device has demonstrated the usefulness of this examination. Nevertheless, Jonas’s recent article raises some questions that must be clarified in light of additional articles that will soon be published by the same author as well as for those who are no longer familiar with ophthalmodynamometry.

The device, as it is described, appears to measure the appositional force exerted by the examiner’s hand on the contact lens placed upon the eye. One has to clearly distinguish between the appositional force and any pressure within the eye itself. In no way does the former reflect any circulatory parameter of the eye, certainly not a collapse pressure. Moreover, this measurement is strongly dependent on the IOP which, in these experiments, seems not to have been considered. The collapse pressure itself strongly depends on the IOP—that is, the tissue pressure around the central retinal vessels, a matter of debate for many years. Since the examination itself lowers the IOP considerably, any repetition of the examination must yield a new value. Therefore, it has been recommended to repeat the examination only after a longer rest period for the eye. If, as cited in this study, the examination has been repeated nine times in succession, the results should show a linear decrease of the distribution curve.

Pulsations of the central retinal vein express the fact that the IOP oscillates at levels near the cerebrospinal fluid pressure, a difference in the order of 1–2 mm Hg. We wonder whether the set-up and the method are accurate enough to document such subtle changes. In order to obtain answers to questions concerning the circulation of the central retinal vessels in the diseases mentioned in the article, it would be necessary to convert the force in the corresponding pressure values. I look forward to reading the articles the author cited in the reference list and to clarification of the points raised in this letter.

Y C A Robert
Triemlispital, Birmensdorferstrasse, 497 Zurich 8044, Switzerland; yves.robert@triemli.sth.ch

References
1 Jonas JB. Reproducibility of ophthalmodynamometric measurements of central retinal artery and vein collapse pressure. Br J Ophthalmol 2003;87:577–9

Time to learn from what is known

We read with interest the recent editorial by Melese et al. Trachoma is responsible for up to two million cases of blindness worldwide, yet to a large extent it is a forgotten disease which affects the poorest and most medically underserved people of the world.

The World Health Organization (WHO), together with the International Agency for Prevention of Blindness, jointly launched “Vision 2020—the right to sight” in 1999 which aims to eliminate avoidable blindness by the year 2020, including blindness from trachoma. WHO has endorsed “SAFE” (Surgery for trichiasis, Antibiotics to reduce the prevalence of chlamydial infection, and Facial cleanliness and Environmental change to reduce the disease transmission) as the strategy implemented by national programmes to achieve the elimination of blinding trachoma. We have recently undertaken a review of the evidence base of the SAFE strategy and judged it to be strong for the surgery and antibiotics components, but weaker for the other components. We therefore concur with the opinion of Melese et al that more research is required, most notably for the rational use of antibiotics, as they suggest, but also to strengthen the evidence relating to the “F” and “E” components.

The SAFE strategy has been implemented by the national trachoma control programmes of many endemic countries in Africa, Asia, and Latin America with varying degrees of success. Melese et al make the observation that the experiences gained from research studies are not directly transferable to real life settings; the need, therefore, is for the publication of the experiences of countries that have successfully dealt with trachoma through implementation of the SAFE strategy to serve as a best practice model for other countries. Morocco is a good example. A decade ago trachoma was a public health problem in five provinces of Morocco, but with the efficient implementation of the SAFE strategy the prevalence of active trachoma and trichiasis has declined dramatically so that Morocco is now close to eliminating trachoma as a public health problem.

Real life country examples such as Morocco documented as case studies allow policy makers and programme managers to learn from the mistakes and successes of public health programmes, because, as Melese et al point out, real life is messy and more complicated than research studies.

H Kuper, J C Buchanan, A Foster
School of Hygiene and Tropical Medicine, 9 Bedford Square, London WC1E 7HT, UK; Hannah.Kuper@lshtm.ac.uk

NOTICES

HIV/AIDS and the eye

The latest issue of Community Eye Health (No 47) discusses the impact of the HIV/AIDS epidemic on prevention of blindness programmes. For further information please contact: Journal of Community Eye Health, International Resource Centre, International Centre for Eye Health, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK (tel: +44 (0)20 7612 7964; email: Anita.Shah@lshtm.ac.uk; website: www.jech.co.uk). Annual subscription (4 issues) UK£28/US$45. Free to developing country applicants.

Second sight

Second Sight, a UK based charity whose aims are to eliminate the backlog of cataract blind in India by the year 2020 and establish strong links between Indian and British ophthalmologists, is regularly sending volunteer surgeons to India. Details can be found at the charity’s website (www.secondsight.org.uk) or by contacting Dr Lucy Mathen (lucymathen@yahoo.com).

Specific Eye Conditions (SPECS)

Specific Eye Conditions (SPECS) is a not for profit organisation which acts as an umbrella organisation for support groups of any conditions or syndrome with an integral eye disorder. SPECS represents over 50 different organisations related to eye disorders ranging from conditions that are relatively common to very rare syndromes. This latest edition is as a portal giving direct access to support groups’ own websites. The SPECS web page is a valuable resource for professionals and may also be of interest to people with a visual impairment or who are blind. For further details about SPECS, contact: Kay Parkinson, SPECS Development Officer (tel: +44 (0)1803 524238; email: k@eyeconditions.org.uk; website: www.eyeconditions.org.uk).

The British Retinitis Pigmentosa Society

The British Retinitis Pigmentosa Society (BRPS) was formed in 1975 to bring together people with retinitis pigmentosa and their families. The principle aims of BRPS are to raise funds to support the programmes of medical research into the eventual cure for this hereditary disease, and through the BRPS welfare service, help members and their families cope with the everyday concerns caused by retinitis pigmentosa. Part of the welfare service is the telephone help line (+44 (0)1280 860 363) for any queries relating to retinitis pigmentosa, especially for those recently diagnosed with retinitis pigmentosa (tel: +44 (0)1280 860 334; email: lynda@brps.demon.co.uk; website: www.brps.demon.co.uk).

Surgical Eye Expeditions International

Volunteer ophthalmologists in active surgical practice are needed to participate in short term sight restoring surgical clinics around the world. Contact: Harry S Brown, Surgical Eye Expeditions International, 27 East De La Guerra, C-2, Santa Barbara, CA 93101-9838, USA (tel: +805 963 3303; fax: +805 963 3354; email: hsbrown.md@cox.net or seeinl@sceinl.org; website: www.sceinl.org).

Rise in organ transplant numbers

According to UK Transplant, the UK has seen the highest number of organ transplants in six years. Last year (1 April 2002 to 31 March 2003), 2777 patients had their lives saved or
dramatically improved through the generosity of 1064 donors. This equated to a 6% increase compared to the previous 12 months (1 April 2001 to 31 March 2002). Furthermore, during 2002–3, the highest number of people benefited from a cornea transplant for five years (1997-98) and 240 more people had their sight restored than the previous year. For further information see UK Transplant’s website (www.uktransplant.org.uk).

Elimination of avoidable blindness

The 56th World Health Assembly (WHA) considered the report on the elimination of avoidable blindness (doc A56/26) and urged Member States to: (1) Commit themselves to supporting the Global Initiative for the Elimination of Avoidable Blindness by setting up a national Vision 2020 plan by 2005; (2) Establish a national coordinating committee for Vision 2020, or a national blindness prevention committee to help implement the plan; (3) Implement the plan by 2007; (4) Include effective monitoring and evaluation of the plan with the aim of showing a reduction in the magnitude of avoidable blindness by 2010; (5) To support the mobilisation of resources for eliminating avoidable blindness. The WHA also urged the Director-General to maintain and strengthen WHO’s collaboration with Member States and the partners of the Global Initiative for the Elimination of Avoidable Blindness as well as aid in the coordination and support of national capability.

5th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT)
The 5th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) will take place 11-14 March 2004, in Monte Carlo, Monaco. Please visit our website for details of the scientific programme, registration, and accommodation. To receive a copy of the Call for Abstracts and registration brochure, please submit your full mailing details to http://www.kenes.com/isopt/interest.htm.


XVth Meeting of the International Neuro-Ophthalmology Society

4th International Congress on Autoimmunity
The 4th International Congress on Autoimmunity will take place 3–7 November 2004 in Budapest, Hungary. The deadline for the receipt of abstracts is 20 June 2004. Further details: Kenes International Global Congress Organisers and Association Management Services, 17 Rue du Cendrier, PO Box 1726, CH-1211 Geneva 1, Switzerland (tel: +41 22 908 0488; fax: +41 22 732 2850; email: autoim04@kenes.com; website: www.kenes.com/autoim2004).

14th Meeting of the EASD Eye Complication study group

The 14th Meeting of the EASD Eye Complication (EASDEC) study group will take place on the 21–23 May 2004. There will be key lecture notes on the following topics: Peter Gaede (Denmark)—Results of the Steno 2 study. Hans Peter Harnes (Germany)—Animal models of diabetic retinopathy, Massimo Porta (Italy)—Screening with the London protocols: 12 years after, and Anselm Kampik (Germany)—Surgical options in diabetic retinopathy. There will also be case presentations and oral and poster presentations. The EASDEC board comprises F Bandello (President), PJ Guilliausseau (Vice President), C-D Agardh (Past President), P Massin (Secretary), M Porta (Treasurer). The Scientific and Organizing Committee includes: F Bandello, PJ Guilliausseau, P Massin, C-D Agardh, M Porta, A Kampik, M Ulbig, and G Lang. There are three travel grants available, at 1000 Euro each, for young scientists (less than 35 years at the time of the meeting). Application for the grant should be made together with the submission of the abstract. For further information, contact: Department of Ophthalmology, Ingrid Mannl, Ludwig-Maximilians-University, Mathildenh- str. 8, 80336 MUNICH, Germany (tel: +49–89–5160–3800; fax: +49–89–5160–4778; e-mail: easdec@ak-l.med.uni-muenchen.de. The deadline for abstracts is 2 March 2004.
Posterior uveal effusion syndrome after trabeculectomy in an eye with ocular venous congestion
N Bhagat, J I Lim, D S Minckler and R L Green

doi: 10.1136/bjo.88.1.153

Updated information and services can be found at:
http://bjo.bmj.com/content/88/1/153

These include:

References
This article cites 5 articles, 0 of which you can access for free at:
http://bjo.bmj.com/content/88/1/153#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/